230 related articles for article (PubMed ID: 16134002)
1. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.
Knudsen JF; Carlsson U; Hammarström P; Sokol GH; Cantilena LR
Inflammation; 2004 Oct; 28(5):285-90. PubMed ID: 16134002
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
Di Fiore A; Pedone C; D'Ambrosio K; Scozzafava A; De Simone G; Supuran CT
Bioorg Med Chem Lett; 2006 Jan; 16(2):437-42. PubMed ID: 16290146
[TBL] [Abstract][Full Text] [Related]
3. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
Weber A; Casini A; Heine A; Kuhn D; Supuran CT; Scozzafava A; Klebe G
J Med Chem; 2004 Jan; 47(3):550-7. PubMed ID: 14736236
[TBL] [Abstract][Full Text] [Related]
4. Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.
Alper AB; Tomlin H; Sadhwani U; Whelton A; Puschett J
Am J Ther; 2006; 13(3):229-35. PubMed ID: 16772765
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy.
Nocentini A; Moi D; Balboni G; Salvadori S; Onnis V; Supuran CT
Bioorg Chem; 2018 Apr; 77():633-639. PubMed ID: 29502024
[TBL] [Abstract][Full Text] [Related]
6. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II.
Katagiri M; Ogasawara T; Hoshi K; Chikazu D; Kimoto A; Noguchi M; Sasamata M; Harada S; Akama H; Tazaki H; Chung UI; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2006 Feb; 21(2):219-27. PubMed ID: 16418777
[TBL] [Abstract][Full Text] [Related]
7. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.
Supuran CT; Casini A; Mastrolorenzo A; Scozzafava A
Mini Rev Med Chem; 2004 Aug; 4(6):625-32. PubMed ID: 15279596
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and carbonic anhydrase inhibitory activities of new thienyl-substituted pyrazoline benzenesulfonamides.
Mete E; Comez B; Inci Gul H; Gulcin I; Supuran CT
J Enzyme Inhib Med Chem; 2016; 31(sup2):1-5. PubMed ID: 27435177
[TBL] [Abstract][Full Text] [Related]
9. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
[TBL] [Abstract][Full Text] [Related]
10. Dual carbonic anhydrase--cyclooxygenase-2 inhibitors.
Dogné JM; Thiry A; Pratico D; Masereel B; Supuran CT
Curr Top Med Chem; 2007; 7(9):885-91. PubMed ID: 17504133
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
Sethi KK; Vullo D; Verma SM; Tanç M; Carta F; Supuran CT
Bioorg Med Chem; 2013 Oct; 21(19):5973-82. PubMed ID: 23965175
[TBL] [Abstract][Full Text] [Related]
12. Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649).
Kim HT; Cha H; Hwang KY
Biochem Biophys Res Commun; 2016 Sep; 478(1):1-6. PubMed ID: 27475498
[TBL] [Abstract][Full Text] [Related]
13. Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds.
Iyer R; Barrese AA; Parakh S; Parker CN; Tripp BC
J Biomol Screen; 2006 Oct; 11(7):782-91. PubMed ID: 16858005
[TBL] [Abstract][Full Text] [Related]
14. Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Gassani BC; Rezende RM; Paiva-Lima P; Ferreira-Alves DL; dos Reis WG; Bakhle YS; de Francischi JN
Pharmacol Res; 2010 Nov; 62(5):439-43. PubMed ID: 20600917
[TBL] [Abstract][Full Text] [Related]
15. Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer.
De Monte C; Carradori S; Gentili A; Mollica A; Trisciuoglio D; Supuran CT
Curr Med Chem; 2015; 22(24):2812-8. PubMed ID: 26180003
[TBL] [Abstract][Full Text] [Related]
16. Sulfonamide bearing pyrazolylpyrazolines as potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII.
Khloya P; Ceruso M; Ram S; Supuran CT; Sharma PK
Bioorg Med Chem Lett; 2015 Aug; 25(16):3208-12. PubMed ID: 26105196
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, cytotoxicity and carbonic anhydrase inhibitory activities of new pyrazolines.
Kucukoglu K; Oral F; Aydin T; Yamali C; Algul O; Sakagami H; Gulcin I; Supuran CT; Gul HI
J Enzyme Inhib Med Chem; 2016; 31(sup4):20-24. PubMed ID: 27579806
[TBL] [Abstract][Full Text] [Related]
18. Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.
Gitto R; Agnello S; Ferro S; De Luca L; Vullo D; Brynda J; Mader P; Supuran CT; Chimirri A
J Med Chem; 2010 Mar; 53(6):2401-8. PubMed ID: 20170095
[TBL] [Abstract][Full Text] [Related]
19. Probing the 'bipolar' nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms.
Krasavin M; Korsakov M; Dorogov M; Tuccinardi T; Dedeoglu N; Supuran CT
Eur J Med Chem; 2015 Aug; 101():334-47. PubMed ID: 26160114
[TBL] [Abstract][Full Text] [Related]
20. A class of sulfonamides as carbonic anhydrase I and II inhibitors.
Gokcen T; Gulcin I; Ozturk T; Goren AC
J Enzyme Inhib Med Chem; 2016; 31(sup2):180-188. PubMed ID: 27353698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
